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TO THE EDITOR
The genetic blistering disorder epider-
molysis bullosa (EB) is divided into
three major types, EB simplex, junc-
tional EB (JEB) and dystrophic EB (Fine
et al., 2000) caused by mutations in at
least 10 genes (Uitto and Richard
2004). JEB is characterized by blistering
in the lamina lucida resulting from
mutations in one of the following six
genes: LAMA3, LAMB3, and LAMC2
that encode the subunit polypeptides of
laminin-332 or ITGA6, ITGB4, or
COL17A1 that encode transmembrane
proteins of the hemidesmosome, inte-
grin a6b4 and BP180 (type XVII col-
lagen), respectively (Varki et al., 2006).
Partial deficiency of laminin-332 or
integrin a6b4, or complete deficiency
of BP180 cause generalized non-Herlitz
JEB (nH-JEB, MIM 226650) (Jonkman
et al., 1995; McGrath et al., 1995),
clinically identified by skin blistering
after minor trauma, non-scarring alope-
cia, nail hypoplasia, enamel pitting
(amelogenesis imperfecta), and, in
some patients, EB nevi (Hintner and
Wolff 1982). Immunofluorescence anti-
gen mapping (IFM) of the patients’ skin
is a helpful technique in determining
the level of blister formation and
identifying the deficient protein.
Here, we report the use of IFM to
identify the subtype of EB using skin
from the parents of two deceased
probands. The parents lived in Iraq
and were first cousins (Figure 1a, III-6
and III-7). Their first child (IV-3), a son,
born in 1992 in Iraq, had no skin
problems. Subsequently, the family
had to move to Iran. Their second son
(IV-4), born in 1995 in Tehran, had a
widespread blistering skin condition
thought to be EB (Figure 1e). He spent
all his life in hospital receiving band-
ages and antibiotics, dying aged 9
months. He had no history of hoarse-
ness. The next child (IV-5), a daughter,
also had congenital blistering and died
in hospital at the age of 1 month. In
2000, the family moved as refugees to
Australia. They were referred for possi-
ble prenatal diagnosis in 2002.
The parents denied any previous
family history of EB and they them-
selves had no skin problems. On
examination, their skin and hair were
normal; however, they had dental
anomalies, first noted in the father at
the age of 9 years (Figure 1b). The
father’s teeth showed significant pitting
and horizontal ridging with extensive
loss of enamel. The mother’s teeth had
horizontal ridging (Figure 1c and Figure
S1). Their 13-year-old son’s teeth
showed extensive enamel mottling (Fig-
ure 1d). Roughly, half the parents’
siblings, five of a total of nine, had
abnormal teeth by history. The studies
were conducted with institutional ap-
proval of the experiments, patient con-
sent, and adherence to the Declaration
of Helsinki Principles.
Skin biopsies were taken from the
abdomen of the father and mother in
2002 and tested by IFM with a panel of
monoclonal antibodies (Yiasemides
et al., 2006). IFM showed no reduction
in staining with antibodies to either
type VII collagen (LH7.2), laminin-332
(D4B5; K140; BM165), integrin a6b4
(GOH3; 439-9B), or BP180 (233) and
LAD-1 (123). On the basis of the
abnormal dentition, it was felt that the
deceased children had EB, most prob-
ably the junctional variant. Therefore,
LAMA3, LAMB3, and LAMC2 were
screened but yielded negative results.
Subsequently, the antibodies 1D1 to the
distal C-terminal ectodomain of BP180
(epitope residues 1357–1387) and 1A8c
to the N-terminal endodomain (epitope
residues 155–163) (Owaribe et al.,
1991) (kind gift of Dr Katsushi Owaribe,
Nagoya, Japan) were tested against the
parents’ skin and the immunofluores-
cence signal was found to be signifi-
cantly reduced compared with normal
human skin in both the mother and
father (Figures 2a–d). Thereafter, screen-
ing of COL17A1 with forward primer
FEX10: 50-GCTTTCAATCCCAAACCA
GG-30 and reverse primer REX10: 50-
TGGCAAACATTCTGAGGGTC-30 re-
vealed the heterozygous presence of a
novel deletion mutation COL17A1
c.823delA in exon 10 – numbering
according to Giudice et al. (1992) – in
DNA from both parents and the older,
clinically unaffected son (Figures 2e
and f). Elaborate DNA screening of the
parents showed the absence of glycine
substitutions. Both parents were hetero-
zygous for the single nucleotide poly-
morphisms c.734C/T (p.T/M) and
c.1168T/C (p.A/A). In addition, the
mother was heterozygous for the single
nucleotide polymorphisms c.2212G/A
(p.V/M) and c.3009G/A (p.P/P). The
deletion of A at position c.823 was
predicted to result in a frame-shift and a
novel mis-sequence beginning at amino
acid p.239 and to conclude in a PTC at
position p.291 (COL17A1:c.823delA,
p.T239fs52). Exon 10 codes for part of
the intracellular domain of BP180.
Thus, most likely the deceased children
had a severe form of non-Herlitz JEB
due to the homozygous presence of the
c.823delA COL17A1 mutation.
The mother became pregnant again
in mid-2003 and a prenatal chorionic
Abbreviations: EB, epidermolysis bullosa; IFM, immunofluorescence antigen mapping; JEB, junctional
EB; nH-JEB, non-Herlitz junctional epidermolysis bullosa
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villous sampling was performed at 10
weeks’ gestation, which revealed a
male infant (IV-6) who was a hetero-
zygous carrier of the mutation and was
phenotypically normal at birth. Repeat
skin biopsies were performed on the
parents and also of their older son (IV-3)
to analyze the consequences of the
mutation at mRNA and protein levels.
Keratinocytes were grown from the skin
biopsies and mRNA was extracted
(Jonkman et al., 1997; Molnar et al.,
2000). To investigate the possible pre-
sence of aberrant mRNA transcripts
around the c.823delA mutation, RT-
PCR was performed using the following
oligonucleotides: forward primer
F0529: 50- ATTCGAGTTCGACTGCAG
AG-30 (exon 8) and reverse primer
R1204 50-TGTCCTTGGTCATGAT
GAGC-30 (exon 14). No alternatively
spliced mRNA transcripts were de-
tected on agarose gel (Figure S2).
Subsequently, the amplified products
of 676 bp were purified and sequenced.
The sequence analysis for the hetero-
zygous parents and their older son only
showed mRNA transcribed from the
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Figure 1. Clinical features of the family. (a) The pedigree indicates the consanguinity of the family
members. (b) The heterozygous father’s (III-7) teeth had extensive pitting and horizontal ridging of the
incisors and loss of enamel in the molars; (c) the heterozygous mother’s (III-6) teeth had horizontal
ridging of the enamel; (d) their oldest son’s (IV-3) teeth showed white mottling of the enamel. (e) The baby
born in 1995 (IV-4) had generalized blistering.
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Figure 2. Immunofluorescence staining (bar¼ 50 mm) of BP180 with monoclonal antibody 1D1 of the skin of the parents of the deceased probands (a: mother)
was reduced compared with (b) normal human control skin. Immunofluorescence staining (original magnification 200) of BP180 with monoclonal antibody
1A8c of the skin of the parents of the deceased probands (c: father) was also reduced compared with (d) normal human control skin. Mutation analysis revealed
the heterozygous presence of the c.823delA mutation in the COL17A1 gene in the DNA of the parents and of the two sons alive (e: father). (e) Owing to the
deletion of an A (arrow) in exon 10 a frameshift occurs finally resulting in a PTC. (f) In DNA of normal human control skin, the 1-bp deletion is absent.
(g) Immunoblot of cultured keratinocytes using monoclonal antibody 1A8c against the intracellular domain of BP180 reveals reduced expression of normal
length BP180 protein and the 60 kDa cytoplasmic domain of BP180 after the shedding of the ectodomain in the parental and sib carriers. Lanes: (M) molecular
weight marker, (1) healthy control, (2) son (IV-3), (3) father, (4) mother, and (5) BP180-negative nH-JEB control.
www.jidonline.org 1773
DF Murrell et al.
Diagnosis of EB
wild-type allele, as the mRNA from the
mutated strand was most likely de-
graded by nonsense-mediated RNA
decay (Figure S3). Similarly, immuno-
blotting of keratinocyte extracts (van
Leusden et al., 2001) using 1A8c anti-
body revealed reduced expression of
full-length BP180 in the carriers (Figure
S4), and of the 60-kDa cytoplasmic
domain of BP180 after the ectodomain
has been shed (Figure 2g (Hirako et al.,
1998)). No smaller BP180 molecule of
290 amino acids was detected, exclud-
ing the possibility of a shortened BP180
molecule that could exert a dominant-
negative effect on the wild-type BP180.
In summary, the testing showed (i)
reduced expression of BP180 by mono-
clonal antibodies 1D1 and 1A8c but not
by 233 or 123 in heterozygous carriers
of the mutation; (ii) a new mutation,
COL17A1:c.823delA,p.T239fs52 (Fig-
ure S5), which is postulated to result
in nonsense-mediated mRNA decay, as
there was no stable expression of a
mRNA transcript bearing the mutation
or of a smaller BP180 protein; and (iii)
no aberrant splicing of exon 10 due to
the mutation as the only produced
BP180 was of normal size and no
smaller mRNA transcripts were detected.
A normal male infant (IV-6) was
born in Sydney in March 2005, who
was a heterozygous carrier at the DNA
level. By April 2006 four primary teeth
had erupted, and thus far (August 2006)
no enamel defects have manifested.
There are several unusual features of
this family. First, the two babies with
nH-JEB due to a COL17A1 mutation
had died despite being hospitalized.
Rarely, patients with this type of nH-JEB
die in early life (Hintner and Wolff
1982; Abu Sa’d et al., 2006; Varki et al.,
2006). It is possible that in a more
advanced healthcare setting, the chil-
dren might have survived. The majority
of BP180-deficient nH-JEB cases owing
to PTC mutations in COL17A1 do
survive to adulthood, although the pheno-
type can vary significantly amongst
these, with some having anemia and
growth retardation (Varki et al., 2006).
Secondly, although the reduction of
BP180 in carriers of COL17A1 muta-
tions was reported by us before (Pas-
mooij et al., 2005, 2006, 2007). It is
remarkable that IMF has been used to
suggest the diagnosis of this form of nH-
JEB in carriers where the probands were
already deceased. It is not very un-
common in Australia for families to be
referred for diagnosis only after an
infant dies from EB, before adequate
investigations have been performed on
the infant (DF Murrell, personal experi-
ence) and hence IFM of the parents can
be useful to direct appropriate investi-
gations. Carriers of recessive PTC muta-
tions of COL7A1 in recessive
dystrophic EB cannot be detected using
LH7:2 or other antibodies against col-
lagen VII (Bruckner-Tuderman et al.,
1988). Furthermore, electron micro-
scopy shows a reduced number of
anchoring fibrils in carriers of dys-
trophic EB and of hemidesmosomes in
JEB, but they are not reliable enough for
diagnosis (Tidman and Eady 1986).
One limitation of the use of IFM is that
the only antibodies which gave reduced
staining, 1D1 and 1A8c, are not com-
mercially available and are in limited
supply (Owaribe, personal communica-
tion, 2006); however, the monoclonal
V58 to residues 234–398 of the intra-
cellular domain recently became com-
mercially available (Olaru et al., 2006).
Thirdly, the presence of enamel
defects in carriers of a deletion muta-
tion in COL17A1 is of interest. The
previously reported mutations causing
dental abnormalities in heterozygous
carriers of COL17A1 mutations were all
dominant glycine-substitution muta-
tions, G609D (Tasanen et al., 2000a),
G612R (Tasanen et al., 2000a), G627V
(McGrath et al., 1996), and G633D
(Tasanen et al., 2000b), yet there were
no glycine substitutions in these par-
ents. In a report on mutations in
COL17A1 and LAMB3 causing JEB in
a family, there were two half-sisters of a
proband who were heterozygous for
the COL17A1 mutation C.3781C4T;
p.R1226X, who were reported to have
dental abnormalities (Floeth and Bruck-
ner-Tuderman 1999). Enamel defects
with these appearances (amelogenesis
imperfecta) could also be caused by
one of several enamel gene defects in
this consanguineous family, unrelated
to EB (Masuya et al., 2005; Nakamura
et al., 2006). However, enamel defects
could also be because of an environ-
mental effect causing chronological
hypoplasia of enamel during the period
0–8 years, when enamel is forming. This
may include an acute childhood illness
with prolonged high temperatures or
chronic illness, such as malnutrition or
exposure to high doses of fluoride,
such as from rural well water. If the
amelogenesis imperfecta were because
of the heterozygous COL17A1 muta-
tion, haploinsufficiency would be im-
plicated as the mutant mRNA most
probably is degraded. Although there
were differences between the parents’
COL17A1 polymorphisms, there is no
evidence that these have caused enam-
el defects. Enamel formation is very
sensitive and may not have redundan-
cies that exist in skin to cope with the
loss of one allele. However, in a recent
study we found no enamel abnormal-
ities in carriers of COL17A1-null
mutations (Pasmooij et al., 2007).
Nevertheless, nH-JEB patients with re-
duced expression of BP180, who have
mild localized blistering and normal
scalp hair, all had at least enamel
pitting (Pasmooij et al., 2007). In some
patients with nH-JEB, the dental
anomalies may not be visible in pro-
bands until the primary molars have
erupted at the age of 2–3 years (Naka-
mura et al., 2006) (MF Jonkman,
unpublished data). Clearly, the pre-
sence of dental abnormalities in these
patients is a complex process and may
involve a gene–environment interaction
during development.
In conclusion, these unique cases of
nH-JEB provide several useful insights
into genotype–phenotype correlation:
(a) nH-JEB caused by COL17A1 muta-
tions may be lethal in the first year of
life; (b) diagnosis of BP180-deficient
nH-JEB can be made from IFM of
heterozygous carrier parents with 1D1
or 1A8c antibodies, at least for the
c.823delA mutation; and (c) the novel
mutation COL17A1:c.823delA results
in a downstream PTC with nonsense-
mediated decay of the abnormal tran-
script. The finding of enamel defects in
the heterozygous carriers was difficult
to explain by purely the reduction in
BP180 protein expression, and may
have been owing to other factors.
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SUPPLEMENTARY MATERIAL
Figure S1. This picture illustrates the horizontal
ridging of the enamel in the incisors of the mother
(III:6).
Figure S2. RT-PCR of exon 10:The gel shows bands
generated by RT-PCR of exon 10 of COL17A1 from
mRNA extracted from skin biopsies.
Figure S3. RT-PCR performed on mRNA of
cultured keratinocytes of the heterozygous father
and mother showed the absence of mRNA from
the c.823delA mutation-bearing allele.
Figure S4. Immunoblotting of similar amounts of
cultured keratinocyte extracts from the brother (1),
father (2), mother (3), and normal control (4)
showing a normal size 180 kd band of the BP180
protein in each.
Figure S5. Schematic diagram of the exons (gray
and black) in COL17A1 showing the location of
all previously reported mutations, with the red
arrow indicating the mutation in this report in
exon 10.
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